Repository Corticotropin Injection (Acthar® Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study

David Wirta, Eugene McLaurin, George Ousler, Jingyu Liu, R Oktay Kacmaz, Joseph Grieco, David Wirta, Eugene McLaurin, George Ousler, Jingyu Liu, R Oktay Kacmaz, Joseph Grieco

Abstract

Introduction: Noninfectious keratitis is a painful corneal inflammation treated with topical cyclosporine and other immunosuppressants. Additional treatment options are needed for keratitis that does not improve with standard therapies. Repository corticotropin injection (RCI; Acthar® Gel) is approved to treat severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, including keratitis. This phase 4, multicenter, open-label study assessed the efficacy and safety of RCI for refractory severe noninfectious keratitis.

Methods: Patients were ≥ 18 years old with persistent severe keratitis despite treatment with topical immunosuppressants. Patients received 80 U of RCI subcutaneously twice weekly for 12 weeks followed by a 4-week taper. Assessments included all domains of the Impact of Dry Eye on Everyday Life (IDEEL) Questionnaire, Ocular Discomfort and 4-Symptom Questionnaire, and Visual Analog Scale (VAS). Corneal fluorescein and conjunctival lissamine green staining, Conjunctival Redness Scale, tear production (Schirmer's test), visual acuity, slit lamp examination, and intraocular pressure were also assessed. Safety was evaluated via treatment-emergent adverse events. Analyses were performed using the modified intent-to-treat (mITT) population (patients who received ≥ 1 dose of RCI and contributed any post-baseline efficacy data).

Results: In the mITT population (N = 35), 50.0% (95% confidence interval, 33.2% to 66.8%) of patients experienced clinically important improvements in the symptom bother domain of the IDEEL Questionnaire at week 12 of RCI therapy. All domains of the IDEEL and the Ocular Discomfort and 4-Symptom Questionnaire showed improvements at week 12 of RCI treatment. The most pronounced improvements in the VAS at week 12 were for eye dryness and eye discomfort. Corneal staining, conjunctival staining, conjunctival redness, and tear production showed early improvements that were sustained through week 12. No new safety signals for RCI were identified.

Conclusions: RCI is safe and effective for refractory severe noninfectious keratitis that has not improved with other approved therapies.

Trial registration number: ClinicalTrials.gov NCT04169061.

Keywords: Acthar Gel; Corneal inflammation; Keratitis; Repository corticotropin injection.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Study design and data collection. BCVA best-corrected visual acuity, BIW twice weekly, IDEEL Impact of Dry Eye on Everyday Life, RCI repository corticotropin injection, TEAE treatment-emergent adverse event, SC subcutaneous, VAS Visual Analog Scale
Fig. 2
Fig. 2
Change from baseline for each domain of the IDEEL Questionnaire. Data are mean (95% confidence interval)
Fig. 3
Fig. 3
Changes from baseline for each item of the Ocular Discomfort and 4-Symptom Questionnaire. Data are mean (95% confidence interval)

References

    1. Singh P, Gupta A, Tripathy K. Keratitis. StatPearls [Internet] Treasure Island: StatPearls Publishing; 2020.
    1. Srigyan D, Gupta M, Behera H. Keratitis: an inflammation of cornea. EC Ophthalmol. 2017:171–7.
    1. Srinivasan M, Mascarenhas J, Prashanth CN. Distinguishing infective versus noninfective keratitis. Indian J Ophthalmol. 2008;56(3):203–207. doi: 10.4103/0301-4738.40358.
    1. Dargin JM, Lowenstein RA. The painful eye. Emerg Med Clin North Am. 2008;26(1):199–216. doi: 10.1016/j.emc.2007.10.001.
    1. Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, Lin A, Rhee MK, et al. Dry eye syndrome preferred practice pattern. Ophthalmology. 2019;126(1):P286–P334. doi: 10.1016/j.ophtha.2018.10.023.
    1. Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011;56(6):474–510. doi: 10.1016/j.survophthal.2011.05.003.
    1. Acthar Gel [package insert]. Bedminster: Mallinckrodt Pharmaceuticals; 2021.
    1. Huang YJ, Galen K, Zweifel B, Brooks LR, Wright AD. Distinct binding and signaling activity of Acthar Gel compared to other melanocortin receptor agonists. J Recept Signal Transduct Res. 2020:1–9.
    1. Decker DA, Grant C, Oh L, Becker PM, Young D, Jordan S. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus. Lupus. 2014;23(8):802–812. doi: 10.1177/0961203314531840.
    1. Olsen NJ, Decker DA, Higgins P, Becker PM, McAloose CA, Benko AL, et al. Direct effects of HP Acthar Gel on human B lymphocyte activation in vitro. Arthritis Res Ther. 2015;17:300. doi: 10.1186/s13075-015-0823-y.
    1. Higgins P, Decker D, Becker P. Immunomodulatory effects of repository corticotropin injection (H.P. Acthar® gel) on the MRL/lpr model of lupus. J Immunol. 2016;196(suppl 1):210–211.
    1. Healy LM, Jang JH, Lin YH, Rao V, Antel JP, Wright D. Melanocortin receptor mediated anti-inflammatory effect of repository corticotropin injection on human monocyte-derived macrophages [ECTRIMS-ACTRIMS abstract EP1481] Mult Scler J. 2017;23(suppl 3):777.
    1. Benko AL, McAloose CA, Becker PM, Wright D, Sunyer T, Kawasawa YI, et al. Repository corticotrophin injection exerts direct acute effects on human B cell gene expression distinct from the actions of glucocorticoids. Clin Exp Immunol. 2018;192(1):68–81. doi: 10.1111/cei.13089.
    1. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1–29. doi: 10.1124/pr.56.1.1.
    1. Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S. The melanocortin system in control of inflammation. Sci World J. 2010;10:1840–1853. doi: 10.1100/tsw.2010.173.
    1. Taylor AW, Lee D. Applications of the role of alpha-MSH in ocular immune privilege. Adv Exp Med Biol. 2010;681:143–149. doi: 10.1007/978-1-4419-6354-3_12.
    1. Taylor AW. Immunosuppressive and anti-inflammatory molecules that maintain immune privilege of the eye. Reference module in neuroscience and biobehavioral psychology. Elsevier; 2017.
    1. Furie R, Mitrane M, Zhao E, Das M, Li D, Becker PM. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. Lupus Sci Med. 2016;3(1):e000180. doi: 10.1136/lupus-2016-000180.
    1. Fleischmann R, Furst DE, Connolly-Strong E, Liu J, Zhu J, Brasington R. Repository corticotropin injection for active rheumatoid arthritis despite aggressive treatment: a randomized controlled withdrawal trial. Rheumatol Ther. 2020;7(2):327–344. doi: 10.1007/s40744-020-00199-3.
    1. Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA. Repository corticotropin injection for persistently active systemic lupus erythematosus: results from a phase 4, multicenter, randomized, double-blind, placebo-controlled trial. Rheumatol Ther. 2020;7(4):893–908. doi: 10.1007/s40744-020-00236-1.
    1. Kaplan J, Miller T, Baker M, Due B, Zhao E. A prospective observational registry of repository corticotropin injection (Acthar® Gel) for the treatment of multiple sclerosis relapse. Front Neurol. 2020;11(1688):598496. doi: 10.3389/fneur.2020.598496.
    1. Perez VL, Ayres B, Toyos M, Toyos R. Noninfectious keratitis: an expert panel recommendation. Evolve Medical Education LLC; 2019.
    1. Abetz L, Rajagopalan K, Mertzanis P, Begley C, Barnes R, Chalmers R, et al. Development and validation of the Impact of Dry Eye on Everyday Life (IDEEL) Questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients. Health Qual Life Outcomes. 2011;9:111. doi: 10.1186/1477-7525-9-111.
    1. Schirmer O. Studies on the physiology and pathology of the secretion and drainage of tears. Graefe Arch Ophthal. 1903;56:197. doi: 10.1007/BF01946264.
    1. Fairchild CJ, Chalmers RL, Begley CG. Clinically important difference in dry eye: change in IDEEL-symptom bother. Optom Vis Sci. 2008;85(8):699–707. doi: 10.1097/OPX.0b013e3181824e0d.
    1. Mantopoulos D, Cruzat A, Hamrah P. In vivo imaging of corneal inflammation: new tools for clinical practice and research. Semin Ophthalmol. 2010;25(5–6):178–185. doi: 10.3109/08820538.2010.518542.
    1. Leonardi A, Flamion B, Baudouin C. Keratitis in dry eye disease and topical ciclosporin A. Ocul Immunol Inflamm. 2017;25(4):577–586. doi: 10.1080/09273948.2016.1276933.
    1. Pflugfelder SC, Stern ME. The cornea in keratoconjunctivitis sicca. Exp Eye Res. 2020;201:108295. doi: 10.1016/j.exer.2020.108295.
    1. Constad WH, Bhagat N. Keratitis sicca and dry eye syndrome. Immunol Allergy Clin North Am. 1997;17(1):89–102. doi: 10.1016/S0889-8561(05)70292-7.
    1. Baudouin C, Irkec M, Messmer EM, Benitez-Del-Castillo JM, Bonini S, Figueiredo FC, et al. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. Acta Ophthalmol. 2018;96(2):111–119. doi: 10.1111/aos.13436.
    1. Efron N, Morgan PB. Rethinking contact lens associated keratitis. Clin Exp Optom. 2006;89(5):280–298. doi: 10.1111/j.1444-0938.2006.00069.x.
    1. Verhelst D, Koppen C, Van Looveren J, Meheus A, Tassignon MJ, Belgian Keratitis Study G Clinical, epidemiological and cost aspects of contact lens related infectious keratitis in Belgium: results of a seven-year retrospective study. Bull Soc Belge Ophtalmol. 2005;297:7–15.
    1. Yamaguchi T. Inflammatory response in dry eye. Invest Ophthalmol Vis Sci. 2018;59(14):DES192–DES199. doi: 10.1167/iovs.17-23651.
    1. Taylor AW, Lee DJ. The alpha-melanocyte stimulating hormone induces conversion of effector T cells into treg cells. J Transplant. 2011;2011:246856. doi: 10.1155/2011/246856.
    1. Wright D, Zweifel B, Prabha S, Galen K, Fitch R. Reduced steriodogenic activity of repository corticotropin injection (RCI) induces a distinct cytokine response following T cell activation [EULAR abstract AB0082] Ann Rheum Dis. 2019;78(suppl 2):1504.
    1. Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA. Repository corticotropin injection for persistently active systemic lupus erythematosus: results from a phase 4, multicenter, randomized, double-blind, placebo-controlled trial. Rheumatol Ther. 2020;7(4):839–908. doi: 10.1007/s40744-020-00236-1.
    1. Fleischmann R, Furst DE. Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2020;19(8):935–944. doi: 10.1080/14740338.2020.1779219.
    1. Patel PB, Shastri DH, Shelat PK, Shukla AK. Ophthalmic drug delivery system: challenges and approaches. Sys Rev Pharm. 2010;1(2):113–120. doi: 10.4103/0975-8453.75042.
    1. Vandenbroeck S, De Geest S, Dobbels F, Fieuws S, Stalmans I, Zeyen T. Prevalence and correlates of self-reported nonadherence with eye drop treatment: the Belgian Compliance Study in Ophthalmology (BCSO) J Glaucoma. 2011;20(7):414–421. doi: 10.1097/IJG.0b013e3181f7b10e.
    1. Zlatanovic G, Veselinovic D, Cekic S, Zivkovic M, Dordevic-Jocic J, Zlatanovic M. Ocular manifestation of rheumatoid arthritis-different forms and frequency. Bosn J Basic Med Sci. 2010;10(4):323–327. doi: 10.17305/bjbms.2010.2680.
    1. Shoughy SS, Tabbara KF. Ocular findings in systemic lupus erythematosus. Saudi J Ophthalmol. 2016;30(2):117–121. doi: 10.1016/j.sjopt.2016.02.001.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner